-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
iTeos Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2019 to Q2 2024.
- iTeos Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $2.26M, a 83.5% increase year-over-year.
- iTeos Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $5.66M, a 224% increase year-over-year.
- iTeos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $3.61M, a 93.1% decline from 2022.
- iTeos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $52.1M, a 24.2% increase from 2021.
- iTeos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $41.9M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)